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The safety and efficacy of an accelerated iron sucrose dosing
regimen in patients with chronic kidney disease.
Background. Provision of adequate iron to support erythro-
poiesis in patients with chronic kidney disease (CKD) is time
consuming and may present adherence problems for patients
in the outpatient setting. We studied an accelerated regimen
of high-dose intravenous iron sucrose therapy in a cohort of
iron-deficient, anemic CKD patients.
Methods. Intravenous iron sucrose 500 mg was infused over
three hours on two consecutive days in 107 CKD patients
(glomerular filtration rate, 32.3 19.6 mL/min/1.73m2, baseline
hemoglobin 10.2  1.7 g/dL). Iron indices (transferrin satura-
tion, ferritin) were measured at baseline and at two and seven
days after completion of the iron regimen. Blood pressures
were monitored immediately prior to, and hourly throughout
the iron sucrose infusions.
Results. Transferrin saturation and serum ferritin increased
from 18.5 8.5% and 177 123.8 ng/mL at baseline to 40.2
22.3% and 811  294.1 ng/mL in 102 evaluated patients (P 
0.015). In 55 patients with additional measurements at 7 days
post-dosing, the transferrin saturation and ferritin had fallen
to 26.3  10.6% and 691  261.8 ng/mL (P  0.015 compared
to two days’ post-dose). Blood pressure rose slightly, but not
significantly, throughout the infusions, and altering the infusion
rate was not necessary. Two patients had seven adverse events
that were considered related to iron sucrose.
Conclusion. An accelerated regimen of high-dose intrave-
nous iron sucrose therapy in CKD patients is safe and effective
in restoring iron stores, and may potentially save time and
improve patient adherence.
The provision of adequate iron to support erythropoi-
esis in iron-deficient patients with chronic kidney disease
is often a time-consuming process that strains the re-
sources of clinicians and challenges patient compliance
to the dosing regimen. In the United States iron sucrose is
approved for the replenishment of iron stores in patients
undergoing hemodialysis and erythropoietic therapy.
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Administration of 100 mg doses over 5 minutes three
times a week for 10 doses is the fastest approved regimen,
although other dosing schemes have been investigated
in both dialysis and predialysis patients [1–9].
In particular, a number of reports have investigated
an iron sucrose dosing regimen that utilized a 500 mg
dose over various infusion times [2–9]. These studies
have been conducted mostly in dialysis patients [2–7],
although some data exist regarding predialysis chronic
kidney disease patients [6, 8, 9]. Generally, these regi-
mens have involved single doses, although 2 weekly
doses have been reported [2, 4, 5, 7, 8, 9]. Concern has
been raised over the safety of these regimens, and
whether the dosage or infusion rate is too high [5, 6].
We prospectively studied a high dose intravenous iron
sucrose regimen utilizing an accelerated dosing fre-
quency in chronic kidney disease patients and now report
on the safety and efficacy of such a regimen.
METHODS
In this prospective study the population of study pa-
tients was drawn from those patients seen by the Division
of Nephrology at Long Island College Hospital in Brook-
lyn, New York. Patients were eligible if the serum ferritin
value was less than 500 ng/mL or the transferrin satura-
tion was less than 40%. This cohort consisted of both
hospitalized patients and outpatients who may or may
not have been already receiving oral iron therapy prior
to the study. A history of intolerance to either oral iron
preparations or iron dextran was not considered a contra-
indication to participation in this study. Patients were
excluded from the study if they were hemodynamically
unstable, had active bleeding or infections, or were nau-
seated or vomiting. Although the patients were typically
anemic, a maximal baseline hemoglobin value was not
considered in determining eligibility for this study. Pa-
tients did not receive red blood cell transfusions for 2
weeks prior to or during the study period.
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Table 1. Baseline clinical demographic and laboratory parameters in the different cohort subsets
N  102 N  55 N  26 N  17
Male/female 37/65 20/35 7/19 7/10
Ethnicity (W/B/H/A) 24/54/20/4 11/27/15/2 5/12/8/1 4/7/6/0
Age years 64.713.9 63.914 65.811.8 6313
Weight kg 83.521 84.822.8 90.421.6 90.921.7
BSA m2 1.90.25 1.90.28 2.00.26 2.00.24
GFR 32.019.1 32.119.1 23.114 23.514.3
Hb g/dL 10.21.7 10.61.8 10.51.6 11.21.2
TSAT % 18.58.5 19.17.4 18.57.1 17.96.2
Ferritin ng/mL 177123.8 159109.9 11689 10596
EPO/NESP/none 32/11/59 12/8/35 10/11/5 5/5/7/0
Abbreviations are: W, white; B, black; H, Hispanic; A, Asian; BSA, body surface area; GFR, glomerular filtration rate; Hb, hemoglobin; TSAT, transferrin
saturation; EPO, erythropoietin; NESP, darbepoietin. There were 102 patients who had baseline and 2 day postdose iron studies performed, 55 patients who had
baseline, 2, and 7 day postdose iron studies performed, 26 patients who received a second 1000 mg dosing regimen and had iron studies performed at baseline and
2 days postdose, and 17 patients who received a second 1000 mg dosing regimen and had iron studies performed at baseline, 2, and 7 days postdose
The dosing regimen employed two doses of intrave-
nous iron sucrose 500 mg, diluted in 250 mL of 0.9%
NaCl injection and infused over three hours on two con-
secutive days (total dose, 1000 mg). If deemed clinically
necessary this dosing regimen was repeated within two
months after the initial treatment. Prior to iron adminis-
tration, baseline data including age, weight, height, gen-
der, ethnicity, glomerular filtration rate [estimated by
the Modification of Diet in Renal Disease (MDRD) for-
mula], erythropoietic therapy regimen, hemoglobin, fer-
ritin, and transferrin saturation were obtained. During
the infusions the systolic and diastolic blood pressures
were recorded at the start and at hourly intervals until
the end of the infusion. Any adverse events occurring
during or subsequent to the infusions were noted and
recorded. Further determinations of the serum ferritin
concentration and transferrin saturation were made two
days and seven days after the final dose of iron sucrose.
All values are expressed as mean and standard devia-
tions. The body surface area was calculated as the square
root of the height in inches multiplied by the weight in
pounds and divided by 3131. The ferritin and transferrin
saturations were compared at baseline and days two and
seven, and the systolic and diastolic blood pressures were
compared pre-treatment and at one, two, and three hours
by analysis of variance, repeated measures to detect dif-
ferences across time. Paired t tests were used to contrast
one time point with another, with a “Bonferroni-type”
adjustment made for the multiple comparisons. A P
value of 0.015 was deemed statistically significant. All
data were transformed (square root) in order to uphold
the normality assumptions of the model. The correlation
between the change in ferritin concentration and body
surface area was expressed by the Spearman-rank coef-
ficient. In this case a P value of 0.05 or less was considered
to be statistically significant.
RESULTS
Initially, 108 patients were entered into the study, in-
cluding two hemodialysis and three peritoneal dialysis
Table 2. Changes in iron indices in response to a 3-hour infusion
of iron sucrose
Baseline 2 days 7 days
TSAT % 18.58.5 40.222.3 26.310.6
Ferritin ng/mL 177124 811294 691262
TSAT-2% 18.57.1 42.521.2 25.36.6
Ferritin-2 ng/mL 11689 645213 526180
Abbreviations are: TSAT, transferrin saturation; TSAT-2, transferrin satura-
tion after a second course of 1000 mg iron sucrose; ferritin-2, serum ferritin
concentration after a second course of 1000 mg iron sucrose. There were 102
patients who had iron indices obtained at baseline and 2 days after receiving
1000 mg of iron sucrose. Fifty-five of these patients also had iron indices obtained
7 days postdose. There were 26 patients who received a second course of 1000
mg iron sucrose and who had iron studies done at baseline and 2 days postdose,
and 17 of these patients had additional iron studies done 7 days postdose.
patients, of which 52 were in-patients and 56 outpatients.
After the first dose of iron sucrose, one patient experi-
enced adverse events and did not continue. Additionally,
two patients were lost to follow-up, two other patients
did not have the two-day post dose iron studies per-
formed, and the blood sample for one patient was ob-
tained in the incorrect tube for analysis. This left 102
patients with data available to analyze for efficacy at
two days’ post-dose. Similarly, 55 patients had additional
data at seven days’ post-dose for analysis. The study
population contained, but was not limited to, those pa-
tients undergoing peritoneal dialysis or hemodialysis.
There were 26 patients (four inpatients and 22 outpa-
tients) who, after completing the initial 1 g iron sucrose
regimen, then received a second course of iron sucrose
infusions as outpatients. All 26 patients had repeat iron
studies done at two days, and 17 of these patients also had
seven-day post-dose iron studies performed. Altogether,
107 patients received 266 doses of iron sucrose injection.
Table 1 presents the demographics and selected clinical
characteristics for the cohorts in this report.
The baseline values and the response to iron sucrose
therapy for patients receiving one course of treatment
(1000 mg iron sucrose) are presented in Table 2. The
analysis of variance, repeated measures found a signifi-
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Fig. 1. The mean serum ferritin concentrations in 55 patients at base-
line, and at two and seven days’ post 1000 mg iron sucrose intravenously.
All values were statistically significantly different from each other.
cant effect of time for ferritin, as well as transferrin
saturation (P  0.0001). The serum ferritin increased
from a baseline of 177 123.8 ng/mL to 811 294 ng/mL
at two days’ post-dose, while the transferrin saturation
increased from a baseline of 18.5  8.5 to 40.2  22.3%
at two days’ post-dose, both significant changes (P 
0.015). Six patients had transferrin saturation values be-
tween 90 and 99% at two days’ post-dose, but these
values decreased to below 40% in the three patients who
had a repeated measurement at seven days’ post-dose.
In the 55 patients that had additional iron studies per-
formed seven days’ post-dose, the ferritin increased from
a baseline value of 159  110 to 828  288 ng/mL at
two days’ post-dose, and then at seven days’ post-dose
was 691  262 ng/mL (P  0.015) (Fig. 1). There were
17 patients (31%) at seven days’ post-dose with ferritin
values above 800 ng/mL, with a maximal value of 1412
ng/mL. Similarly, the transferrin saturation increased
from 19.1  7.4 to 47.3  24.3 and then decreased to a
seven-day post-dose value of 26.3  10.6% (P  0.015)
(Fig. 2).
In the 26 patients that received a second treatment
course of iron sucrose, all had two-day post-dose iron
studies obtained, and 17 of these patients also had seven-
day post-dose studies completed (Table 2). The changes
in iron status subsequent to the second treatment course
paralleled those seen in the patients who received only
one treatment course; namely, the ferritin increased from
the baseline value of 116  89 to 645  213 ng/mL at
two days’ post-dose, while transferrin saturation in-
creased from 18.5 7.1 to 42.5 21.2%, both statistically
significant changes. For the 17 patients who had iron
studies done additionally at seven days’ post-dose, the
ferritin increased from 105  96 to 603  165 at two
days’ post-dose and was 526  180 ng/mL at seven days’
post-dose, all significant changes. Transferrin saturation
in the 17 patients started at 17.9  6.2 and increased to
Fig. 2. The mean transferrin saturations in 55 patients at baseline, and
at two and seven days’ post 1000 mg iron sucrose intravenously. All
values were statistically significantly different from each other.
42.2  18 at two days’ post-dose, and was 25.3  6.6%
at seven days’ post-dose, again with all changes being
significantly different.
In the 102 patients who had iron studies two days’
post-dose, the normalized iron dosage was 1103  144
mg per 1.73m2 of body surface area. The change from
baseline of the serum ferritin correlated inversely with
the body surface area (r0.524, P 0.01), demonstra-
ting that the change in serum ferritin values was less for
patients with larger body surface areas than for patients
with smaller body surface areas when the same iron
sucrose dose (1000 mg) is given.
Blood pressure response to the two iron sucrose infu-
sions in 107 patients is reported in Table 3 and includes
baseline and hourly values until completion of the infu-
sions. It was not necessary to adjust the infusion rate for
any patient based upon a change in blood pressure, nor
were any additional pre-infusion or intra-infusion medi-
cations given. Blood pressures increased slightly during
the infusion, with the systolic blood pressure rising from
138.1  20 pre-infusion to 140.7  21.6 mm Hg at the
end of the infusion (mean change, 2.6 mm Hg) and the
diastolic blood pressure rising from 74.6 12.1 to 75.9
12.2 mm Hg at the end of the infusion (mean change,
1.3 mm Hg). Both of these blood pressure changes over
time were neither clinically nor statistically significant
(P  0.11). Similar blood pressure responses were seen
in the 26 patients who received a second course of iron
sucrose therapy (data not shown).
Overall, iron sucrose was well tolerated by most pa-
tients. A total of 10 adverse events were observed in five
patients, of which seven adverse events in two patients
were considered definitely related to drug administra-
tion. This adverse event profile represents a rate of 4.6%
of patients having reactions during therapy, and 1.8%
of patients experiencing adverse events attributed to iron
sucrose. Similarly, this data can be expressed as a rate
of patients having adverse events during 266 infusions
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Table 3. Blood pressure response to a 3-hour infusion of 500 mg iron sucrose in 107 patients
Blood pressure Pre-infusion 1 hour 2 hours 3 hours
Systolic 138.120.0 139.319.6 140.220.2 140.721.6
Diastolic 74.612.1 75.611.7 75.611.4 75.912.2
of iron sucrose; 0.19% of patients had adverse events and
0.08% of patients had definitely related adverse events
during 266 infusions.
In one patient receiving their first iron sucrose infu-
sion, epigastric discomfort, nausea, vomiting, and light-
headedness developed during the infusion. These events
precluded subsequent iron sucrose infusions, and the
patient was discontinued from further study. The second
patient experienced abdominal cramps and moderate
nausea lasting three days after completing the course
of iron sucrose therapy. One patient experienced two
possible iron sucrose–related adverse events, mild nau-
sea and diarrhea, which occurred the day after comple-
tion of the treatment course. Two patients experienced
two adverse events temporally related to iron sucrose,
but these events were considered not related to the treat-
ment. One patient experienced a sensation of upper body
heat, which occurred hours after the first infusion, but
tolerated three more 500 mg infusions without recur-
rence. The fifth patient reported several minutes of dia-
phoresis occurring 2 hours after an infusion.
DISCUSSION
The iron sucrose dosage regimen employed was effec-
tive in rapidly increasing indices of iron status in our
study population. The mean baseline value of the trans-
ferrin saturation was below 20%, the level at which iron
therapy should be given to anemic patients with chronic
kidney disease [10]. Although six patients had transferrin
saturation values between 90% and 99% two days’ post-
dose, in the three patients who had repeated measure-
ments seven days’ post-dose, the values had decreased
to below the maximum recommended level of 50%. The
mean transferrin saturation at seven days’ post-dose was
significantly lower than the value at two days’ post-dose.
Similarly, the mean serum ferritin value at baseline
was above the 100 ng/mL National Kidney Foundation-
Kidney Disease Outcomes Quality Initiative (NKF-K/
DOQI) Clinical Practice Guidelines value indicating ab-
solute iron deficiency, and two days’ post-dose had in-
creased to slightly above 800 mg/mL, the level at which
NKF-K/DOQI recommends holding additional iron
therapy [10]. The mean serum ferritin level had fallen
to just below 700 ng/mL in those patients who had mea-
surements seven days’ post-dose, significantly different
from the two-day post-dose value. Seventeen patients
(31%) had ferritin values greater than 800 ng/mL at
seven days’ post-dose, although no toxicity could be at-
tributed to this. In addition, we demonstrated an inverse
correlation between change in ferritin concentration
from baseline and the patient’s body surface area.
Iron sucrose injection has been available for clinical
use for more than 50 years in Europe and for about
three years in the United States. Of particular interest
is its employment in patients with chronic kidney disease,
although in the United States the official product labeling
only states that iron sucrose may be used in the treatment
of iron deficiency anemia in hemodialysis patients receiv-
ing concurrent erythropoietin therapy. The dosing regi-
men specified is 100 mg intravenously one to three times
a week for 10 doses, which may be repeated. Typically,
a dialysis nurse administers the dose when patients come
for their routine hemodialysis treatments. Attempts have
been made to increase the dosage of iron sucrose and
to minimize the frequency of administration, simplifying
the regimen for both the clinician and the patient [1–9].
This may be especially beneficial for anemic, iron-defi-
cient peritoneal dialysis or predialysis patients. Adher-
ence to the medical regimen could potentially be im-
proved with less frequent dosing, there would be a less
frequent need to obtain venous access, and a hematologic
response might be hastened. Although data are currently
lacking, a pharmacoeconomic advantage may be the re-
sult of a high-dose regimen.
There have been a limited number of reports describ-
ing the experience with 500 mg doses of iron sucrose in
anemic, iron-deficient hemodialysis, peritoneal dialysis,
renal transplant, and predialysis chronic kidney disease
patients [2–9]. Although the potential efficacy of such
an approach may be evident, concerns have been raised
regarding acute and chronic toxicity in this dosage range
[6, 11].
Infusion rates of 500 mg doses of iron sucrose have
ranged from 77 to 500 mg/hour (durations of 6.5 hours
to 1 hour, respectively) [2, 4–9], although one report de-
scribed the dosing regimen as only “300 to 800 mg iron
sucrose by intravenous bolus.”[3] The slower administra-
tion rates and extended dosing frequencies have been an
attempt to minimize any potential toxicity. The current
study utilized a rate of 167 mg/hour (three-hour infu-
sion), which would place it mid-range among previous
studies. The most common frequency of dosing has been
either a single dose, or weekly for two doses, although
we previously have described a patient who tolerated
multiple, consecutive daily doses [9], as in the current
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study. The European Best Practice Guidelines suggest
that, in continuous ambulatory peritoneal dialysis (CAPD)
and predialysis patients, 200 to 500 mg of iron sucrose
in 100 to 500 mL saline be infused intravenously over
one to four hours [12].
Iron sucrose in a dosage of 500 mg was well tolerated
in the current study, with only two of 108 patients (1.8%)
having adverse effects attributed to the drug. Only one
patient had adverse effects that, in the judgment of a
clinician, precluded further participation in the study. A
potentially contributing factor for this low toxicity profile
might be the preponderance in the study population of
pre-dialysis patients, and the small number (5) of hemo-
dialysis and peritoneal dialysis patients. Previous reports
have studied both hemodialysis and peritoneal dialysis
patients almost exclusively, and until the present study,
there were only two series that included predialysis or
predialysis and transplant patients [6, 8].
The frequency of adverse events to 500 mg doses of
iron sucrose has been reported to be highly variable,
ranging from 0% to 36% [2–9], making a safety evalua-
tion difficult. As stated above, the study population may
influence susceptibility to toxicity, although there have
been separate reports of no side effects in 21 peritoneal
dialysis patients [4], 17 hemodialysis patients [3], and
20 predialysis patients [8]. One center has studied the
influence of infusion rates on the incidence of side effects
in peritoneal dialysis patients by lengthening the infusion
time from 4.5 hours to 6.5 hours [7]. Side effects were
seen in two of 23 patients (8.7%, or 4.3% of infusions)
in the shorter duration infusion study, including one epi-
sode of anaphylaxis (4.3% of patients, 2.2% of injections)
[5], compared with side effects in four of 46 patients
(8.7% or 4.1% of infusions) in the longer duration infu-
sion study [7]. In contrast to these findings, a study of 21
peritoneal dialysis patients receiving 500 mg iron sucrose
over two hours reported no side effects [4].
Perhaps the most widely noticed study of 500 mg iron
sucrose dosing was a dose ranging investigation that uti-
lized a two hour dosing duration in 10 hemodialysis, five
peritoneal dialysis, one renal transplant, and six predial-
ysis patients [6]. The reported incidence of adverse ef-
fects was 36%, or eight of 22 patients. Two of these
patients were hospitalized for 24 hours as a “safety pre-
caution,” although the specific reason was not stated. All
the patients with side effects were said to have become
hypotensive, although the actual blood pressures at any
time were not reported. The 10 hemodialysis patients
received their iron sucrose dose while being dialyzed,
making an evaluation of the effect of the drug on the
blood pressure more complicated. All patients were
given hydrocortisone and chlorpheniramine intrave-
nously when symptoms developed. All symptoms then
resolved within 15 minutes in five patients, and within
two hours in one patient, while the remaining two pa-
tients were hospitalized for 24 hours. Besides hypoten-
sion, other side effects included nausea, vomiting, back
pain, and bilateral edema of the hands and feet, similar
to what has been observed in other reports of both 500
mg or lower doses and in the current study, except that
we observed slight increases in blood pressures. Interest-
ingly, the side effects attributed to the two-hour dosing
regimen occurred in patients with baseline ferritin levels
of 54 to 104 ng/mL, which the authors believed would
make iron overload an unlikely cause.
In the current study there were 17 of 55 patients with
seven-day post-dose ferritin levels greater than 800
ng/mL, with no apparent adverse effects. The NKF-K/
DOQI guidelines note the difficulty of establishing a
minimal toxic serum ferritin level, and make reference
to a study of chronic renal failure patients with mean
serum ferritin levels slightly more than 1000 ng/mL that
had no evidence of iron overload upon bone marrow
biopsy [10]. We feel that acute and transient elevations
of serum ferritin levels produce no acute symptoms.
This study did not address the subject of chronic toxic-
ity of iron therapy in chronic kidney disease patients,
although there have been theoretical and unproven con-
cerns raised [11]. The other studies of 500 mg iron sucrose
doses have similarly not been designed to answer the
questions of risk of infection, atherosclerosis, or other
toxicities. However, in their study in 23 peritoneal dial-
ysis patients, Prakash et al [5] looked at peritonitis rates
in the six-month period preceding iron sucrose therapy
and compared this with the six-month period subsequent
to iron sucrose. Although there was a trend to more
peritonitis after iron sucrose, statistically there was no
difference demonstrated. Only larger, controlled pro-
spective studies can answer this and other questions con-
cerning any long-term harm from this therapy.
CONCLUSION
This study is the largest series examining high-dose
iron sucrose therapy in patients with chronic kidney dis-
ease. A large variety of patients were included, making
the application of our findings more applicable to the
general nephrology patient population. Improvements
in indices of iron status were achieved, with a very low
cost in toxicity. The accelerated dosing regimen saves
time for health professionals, and may increase the ad-
herence of patients to a prescribed iron sucrose regimen.
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